Paul M Jeene1,2, Kim C de Vries3,4, Johanna G H van Nes5, Johannes J M Kwakman1, Gerda Wester6, Tom Rozema7, Pètra M Braam8, Jaap D Zindler9, Peter Koper10, Joost J Nuyttens4, Hanneke A Vos-Westerman11, Ilona Schmeets12, Charles G H J Niël2, Stefan Hutschemaekers13, Yvette M van der Linden14, Joost J C Verhoeff15, Lukas J A Stalpers1. 1. a Department of Radiotherapy , Academic Medical Center, University of Amsterdam , Amsterdam , The Netherlands. 2. b Radiotherapiegroep , Deventer , The Netherlands. 3. c Department of Radiotherapy , Antoni van Leeuwenhoek ziekenhuis, Netherlands Cancer Institute , Amsterdam , The Netherlands. 4. d Department of Radiotherapy , Erasmus MC Cancer Institute , Rotterdam , The Netherlands. 5. e Radiotherapeutisch Instituut Friesland , Leeuwarden , The Netherlands. 6. f Radiotherapiegroep , Arnhem , The Netherlands. 7. g Instituut Verbeeten , Tilburg , The Netherlands. 8. h Department of Radiotherapy , RadboudUMC , Nijmegen , The Netherlands. 9. i MAASTRO Clinic Maastricht, GROW School for Oncology and Developmental Biology , Maastricht University Medical Centre , Maastricht , The Netherlands. 10. j Department of Radiotherapy , HaaglandenMC , The Hague , The Netherlands. 11. k Department of Radiotherapy , Isala kliniek , Zwolle , The Netherlands. 12. l Department of Radiotherapy , Catharina ziekenhuis , Eindhoven , The Netherlands. 13. m Zuidwest Radiotherapeutisch Instituut , Vlissingen and Roosendaal , The Netherlands. 14. n Department of Radiotherapy , Leids University Medical Centre , Leiden , The Netherlands. 15. o Department of Radiotherapy , University Medical Center Utrecht , Utrecht , The Netherlands.
Abstract
BACKGROUND: Whole brain radiotherapy (WBRT) is considered standard of care for patients with multiple brain metastases or unfit for radical treatment modalities. Recent studies raised discussion about the expected survival after WBRT. Therefore, we analysed survival after WBRT for brain metastases 'in daily practice' in a large nationwide multicentre retrospective cohort. METHODS: Between 2000 and 2014, 6325 patients had WBRT (20 Gy in 4 Gy fractions) for brain metastases from non-small cell lung cancer (NSCLC; 4363 patients) or breast cancer (BC; 1962 patients); patients were treated in 15 out of 21 Dutch radiotherapy centres. Survival was calculated by the Kaplan-Meier method from the first day of WBRT until death as recorded in local hospital data registration or the Dutch Municipal Personal Records Database. FINDINGS: The median survival was 2.7 months for NSCLC and 3.7 months for BC patients (p < .001). For NSCLC patients aged <50, 50-60, 60-70 and >70 years, survival was 4.0, 3.0, 2.8 and 2.1 months, respectively (p < .001). For BC patients, survival was 4.5, 3.8, 3.2 and 2.9 months, respectively (p = .047). In multivariable analyses, higher age was related to poorer survival with hazard ratios (HR) for patients aged 50-60, 60-70 and >70 years being 1.05, 1.19 and 1.34, respectively. Primary BC (HR: 0.83) and female sex (HR: 0.85) were related to better survival (p < .001). INTERPRETATION: The survival of patients after WBRT for brain metastases from NSCLC treated in Dutch 'common radiotherapy practice' is poor, in breast cancer and younger patients it is disappointingly little better. These results are in line with the results presented in the QUARTZ trial and we advocate a much more restrictive use of WBRT. In patients with a more favourable prognosis the optimal treatment strategy remains to be determined. Prospective randomized trials and individualized prognostic models are needed to identify these patients and to tailor treatment.
BACKGROUND: Whole brain radiotherapy (WBRT) is considered standard of care for patients with multiple brain metastases or unfit for radical treatment modalities. Recent studies raised discussion about the expected survival after WBRT. Therefore, we analysed survival after WBRT for brain metastases 'in daily practice' in a large nationwide multicentre retrospective cohort. METHODS: Between 2000 and 2014, 6325 patients had WBRT (20 Gy in 4 Gy fractions) for brain metastases from non-small cell lung cancer (NSCLC; 4363 patients) or breast cancer (BC; 1962 patients); patients were treated in 15 out of 21 Dutch radiotherapy centres. Survival was calculated by the Kaplan-Meier method from the first day of WBRT until death as recorded in local hospital data registration or the Dutch Municipal Personal Records Database. FINDINGS: The median survival was 2.7 months for NSCLC and 3.7 months for BC patients (p < .001). For NSCLCpatients aged <50, 50-60, 60-70 and >70 years, survival was 4.0, 3.0, 2.8 and 2.1 months, respectively (p < .001). For BC patients, survival was 4.5, 3.8, 3.2 and 2.9 months, respectively (p = .047). In multivariable analyses, higher age was related to poorer survival with hazard ratios (HR) for patients aged 50-60, 60-70 and >70 years being 1.05, 1.19 and 1.34, respectively. Primary BC (HR: 0.83) and female sex (HR: 0.85) were related to better survival (p < .001). INTERPRETATION: The survival of patients after WBRT for brain metastases from NSCLC treated in Dutch 'common radiotherapy practice' is poor, in breast cancer and younger patients it is disappointingly little better. These results are in line with the results presented in the QUARTZ trial and we advocate a much more restrictive use of WBRT. In patients with a more favourable prognosis the optimal treatment strategy remains to be determined. Prospective randomized trials and individualized prognostic models are needed to identify these patients and to tailor treatment.
Authors: Matthew N Mills; Thrisha K Potluri; Yuki Kawahara; Matthew Fahey; Nicholas B Figura; Aixa E Soyano; Iman R Washington; Roberto Diaz; Daniel E Oliver; Hsiang-Hsuan Michael Yu; Arnold B Etame; Michael A Vogelbaum; Brian J Czerniecki; John A Arrington; Solmaz Sahebjam; Peter A Forsyth; Hatem H Soliman; Hyo S Han; Kamran A Ahmed Journal: Breast Cancer Res Treat Date: 2021-10-20 Impact factor: 4.872
Authors: Dianne Hartgerink; Britt van der Heijden; Dirk De Ruysscher; Alida Postma; Linda Ackermans; Ann Hoeben; Monique Anten; Philippe Lambin; Karin Terhaag; Arthur Jochems; Andre Dekker; Janna Schoenmaekers; Lizza Hendriks; Jaap Zindler Journal: Front Oncol Date: 2018-05-09 Impact factor: 6.244
Authors: Angelika Bilger; Eva Bretzinger; Jamina Fennell; Carsten Nieder; Hannah Lorenz; Oliver Oehlke; Anca-Ligia Grosu; Hanno M Specht; Stephanie E Combs Journal: Cancer Med Date: 2018-05-09 Impact factor: 4.452